Aktuellt
SENASTE
Vitrolife's previous Q2 confirmed a significant recovery from the very soft comparable period in 2020 that COVID disrupted. Q3 is usually a period of weaker growth due to holidays. This year the Q3 is a positive surprise extending the positive momentum from the previous quarter. Both the top-line and the EBITDA margin are strong, confirming the support from operational leverage. The recovery is also evenly spread between regions, and the operating leverage is mainly a result of the gross margin support. We expect both a positive immediate share price reaction and structural support ahead.
LÄS MER
